Evolving pattern of platelet P2Y₁₂ inhibition in patients with acute coronary syndromes

References

• World Health Organization. Cardiovascular diseases (CVDs). Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html [last accessed March 2013]
   Google Scholar
• Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914–918
   PubMed Web of Science ®Google Scholar
• Gachet C. P2 receptors, platelet function and pharmacological implications. Thrombos Haemostas 2008;99:466–472
   PubMed Web of Science ®Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharmaceut Design 2006;12:1255–1259
   PubMed Web of Science ®Google Scholar
• Bassand J-P, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KAA, Hasdai D, Ohman EM, Wallentin L, et al. Task force for diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of European society of cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598–1660
   PubMed Web of Science ®Google Scholar
• Ahmad S, Storey RF. Development and clinical use of prasugrel and ticagrelor. Curr Pharmaceut Design 2012;18:5240–5260
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996;348:1329–1339
   PubMed Web of Science ®Google Scholar
• The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New Engl J Med 2005;352:1179–1189
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–2913
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 2009;120:2577–2585
   PubMed Web of Science ®Google Scholar
• Brandt J, Payne C, Wiviott S, Weerakkody G, Farid N, Small D, Jakubowski J, Naganuma H, Winters K. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9–66.e16
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, et al, for the J-TI. Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine p2y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366–3373
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann F-J, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923–2932
   PubMed Web of Science ®Google Scholar
• Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2007;357:2001–2015
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Available from http://www.nice.org.uk/nicemedia/live/12324/45849/45849.pdf [last accessed October 2009]
   Google Scholar
• Storey RF, Angiolillo D, Patil S, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon C, Becker R, Wallentin L. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO PLATELET substudy. J Am Coll Cardiol 2010;56:1456–1462
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009;361:1045–1057
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Available from http://www.nice.org.uk/nicemedia/live/13588/56819/56819.pdf [last accesssed October 2011]
   Google Scholar
• Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999–3054
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–1856
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment–Elevation myocardial infarction. Circul: Cardiovasc Intervent 2012;5:797–804
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Mavronasiou E, Stavrou K, Siapika A, Tsoni E, Davlouros P. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes mellitus. Diabetes Care 2013;36:2211--2216
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 2007;115:708–716
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008;118:1626–1636
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569–2619
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009;373:723–731
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KAA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297–1309
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601–1606
   PubMed Web of Science ®Google Scholar